Company intelligence / Profile preview

Beijing Tiannuojiancheng Pharma

Beijing, China

Ownership: Private
Development stage: Other

Overview

Tiannuojiancheng Pharma is developing CM369 (ICP-B05), an anti-CCR8 monoclonal antibody, which has received IND approval and dosed first patient in Phase 1 for advanced solid tumors. CM355, a CD20xCD3 bispecific antibody, has also received IND approval and is in clinical trials.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

CM369

Partnerships

InnoCare PharmaKeymed Biosciences

Beyond the preview

Go deeper on Beijing Tiannuojiancheng Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Tiannuojiancheng Pharma.